QuidelOrtho Corp. Aktie
QuidelOrtho Corp. Aktie
Was spricht für und gegen QuidelOrtho Corp. in den nächsten Jahren?
Pro
Kontra
Rendite von QuidelOrtho Corp. im Vergleich
Wertpapier | Ver.(%) | 1W | 1M | 1J | YTD | 3J | 5J |
---|---|---|---|---|---|---|---|
QuidelOrtho Corp. | 0,54 % | 1,09 % | -16,50 % | -54,42 % | -45,15 % | -58,08 % | - |
Boston Scientific | -2,19 % | 6,25 % | 7,19 % | 43,76 % | 32,19 % | 87,07 % | 104,94 % |
Waters Corp. | 0,59 % | 5,21 % | -9,13 % | 6,91 % | -3,71 % | 15,40 % | 52,04 % |
Illumina Inc. | 2,80 % | 2,99 % | -8,67 % | -37,65 % | -9,49 % | -64,70 % | -58,22 % |
Kommentare
News
QuidelOrtho To Report First Quarter 2024 Financial Results
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and
QuidelOrtho Adds Fentanyl Test to Its Vitros® Systems as a MicroTip® Partnership Assay
QuidelOrtho Corporation (Nasdaq: QDEL) has added the ARK™ Fentanyl II Assay to its U.S. Vitros® XT 7600 and 5600 Integrated Systems as well as its Vitros® 4600 Chemistry System menu of assays as a
QuidelOrtho Receives FDA 510(k) Clearance for Its QuickVue® COVID-19 Test
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho" or the “Company”) has received U.S. Food and Drug Administration (“FDA”) 510(k) clearance for its QuickVue COVID-19 test. This clearance allows